1. Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19
- Author
-
Qin, Juan-Juan, Cheng, Xu, Zhou, Feng, Lei, Fang, Akolkar, Gauri, Cai, Jingjing, Zhang, Xiao-Jing, Blet, Alice, Xie, Jing, Zhang, Peng, Liu, Ye-Mao, Huang, Zizhen, Zhao, Ling-Ping, Lin, Lijin, Xia, Meng, Chen, Ming-Ming, Song, Xiaohui, Bai, Liangjie, Chen, Ze, Zhang, Xingyuan, Xiang, Da, Chen, Jing, Xu, Qingbo, Ma, Xin-Liang, Touyz, Rhian M, Gao, Chen, Wang, Haitao, Liu, Liming, Mao, Weiming, Luo, Pengcheng, Yan, Youqin, Ye, Ping, Chen, Manhua, Chen, Guohua, Zhu, Lihua, She, Zhi-Gang, Huang, Xiaodong, Yuan, Yufeng, Zhang, Bing-Hong, Wang, Yibin, Liu, Peter P, and Li, Hongliang
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Heart Disease ,Clinical Research ,Cardiovascular ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Good Health and Well Being ,Betacoronavirus ,Biomarkers ,COVID-19 ,China ,Coronavirus Infections ,Creatine Kinase ,MB Form ,Female ,Heart Diseases ,Hospitalization ,Humans ,Male ,Middle Aged ,Mortality ,Natriuretic Peptide ,Brain ,Outcome Assessment ,Health Care ,Pandemics ,Peptide Fragments ,Pneumonia ,Viral ,Predictive Value of Tests ,Prognosis ,Retrospective Studies ,SARS-CoV-2 ,Troponin I ,biomarkers ,heart diseases ,heart injuries ,mortality ,prognosis ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
The prognostic power of circulating cardiac biomarkers, their utility, and pattern of release in coronavirus disease 2019 (COVID-19) patients have not been clearly defined. In this multicentered retrospective study, we enrolled 3219 patients with diagnosed COVID-19 admitted to 9 hospitals from December 31, 2019 to March 4, 2020, to estimate the associations and prognostic power of circulating cardiac injury markers with the poor outcomes of COVID-19. In the mixed-effects Cox model, after adjusting for age, sex, and comorbidities, the adjusted hazard ratio of 28-day mortality for hs-cTnI (high-sensitivity cardiac troponin I) was 7.12 ([95% CI, 4.60-11.03] P
- Published
- 2020